PubHawk
N Engl J Med September 2014 PMID 25176015

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

John J V McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg, Michael R Zile

Full text PDF Download social card

Mentions

369
Peak: 17 in Jun 2024
across 7 sources since Sep 2014

Extended reach

468,895
potential audience

Total likes

1,081

Video views

103,710

Mentions per month

Sep 2014 – Oct 2025

Where it's discussed

  • News156 articles
  • X / Twitter119 posts
  • Facebook58 posts
  • Blogs22 articles
  • YouTube9 videos
  • Reddit4 posts
  • Bluesky1 posts

AI synopsis

What people are saying

The collective discussions clearly reflect high engagement and agreement, with posts citing pivotal trials like PARADIGM-HF and praising the proven benefits of ARNI therapy; words like 'significant reduction' and 'game-changing' illustrate the impact and enthusiasm, demonstrating the publication’s profound effect on medical practices.

AgreementStrong agreement

Most discussions strongly endorse the findings, emphasizing the superiority of the new ARNI treatment over enalapril.

InterestHigh interest

Participants show high curiosity, referencing detailed trial data and implications for clinical practice.

EngagementHigh engagement

Many posts engage deeply by citing specific studies, trial results, and discussing treatment protocols.

ImpactHigh impact

The dialogues highlight the significant influence of this publication on treatment guidelines and clinical decision-making.

Abstract in brief

  • The study compared LCZ696, an angiotensin receptor-neprilysin inhibitor, with enalapril in patients with heart failure and reduced ejection fraction, finding LCZ696 significantly reduced death and hospitalization rates.
  • The trial was stopped early due to the overwhelming benefits observed with LCZ696, showing a hazard ratio of 0.80 for cardiovascular death or heart failure hospitalization.
  • LCZ696 also decreased symptoms and physical limitations of heart failure, had a different side effect profile (more hypotension and angioedema, but fewer kidney issues and cough) compared to enalapril.]
Read the full abstract

Top posts

Most liked on X and Bluesky
Yash
@DoctorBhavsar · X

Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X https://t.co/lwWgIQ7BiE

Jun 16, 2024 · 94 likes · 16 shares · 3,849 followers View post →
Muthu Vaduganathan
@mvaduganathan · X

Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n #PIONEER acute HFrEF https://t.co/DMWjmkgP9G #PARALLAX chronic HFmREF/HFpEF https://t.co/Eci3ETX1pD #PARAGON/#PARAGLIDE HFmrEF/HFpEF https://t.co/ud4AMPv0Vf https://t.co/jDufkXk40p

Sep 27, 2024 · 47 likes · 13 shares · 9,128 followers View post →
ACCP Cardiology PRN
@accpcardprn · X

#TBT PARADIGM-HF Trial

Apr 14, 2022 · 19 likes · 6 shares · 9,286 followers View post →
Dr. FEVI
@javier20ch · X

✍️Artículos originales:

Feb 14, 2023 · 18 likes · 12 shares · 13,370 followers View post →
Brahmajee Nallamothu
@bnallamo · X

We'll accompany this with the contemporary PARADIGM-HF trial that demonstrated a mortality benefit of angiotensin-neprilysin inhibition over enalapril. https://t.co/45OqSdDz0W

Feb 25, 2020 · 9 likes · 3,435 followers View post →
Conrad Macon
@cjmacon · X

PARADIGM-HF (DOI: 10.1056/NEJMoa1409077) less ⬇️ eGFR w ARNIs than renal protective medication enalapril (-1.61 vs. -2.04; p < 0.001) Increase in urinary albumin/Cr ratio (1.20 vs. 0.90; p < 0.001) (But they excluded eGFR <30) https://t.co/Or7asEHbyY

Dec 6, 2021 · 7 likes · 387 followers View post →

All mentions

Vladis Sokalskis
@vlad_sok · X

RT @MarkusAtHome: Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK) https://t.co/F8MXRSRLKe Prof. McMu…

Oct 17, 2025 · 2 shares · 504 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

RT @MarkusAtHome: Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK) https://t.co/F8MXRSRLKe Prof. McMu…

Oct 17, 2025 · 2 shares · 2,414 followers View post →
markusathome
@markusathome.bsky.social · Bluesky

Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK) youtu.be/kK8N-5RkEfc?... Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.

Oct 17, 2025 · 1 like · 1 share View post →
markusathome
@MarkusAtHome · X

Novel developments in the treatment of HFrEF - Prof. Dr. John McMurray (Glasgow, UK) https://t.co/F8MXRSRLKe Prof. McMurray discusses new developments in the treatment of HFrEF, focusing on new outcome data for vericiguat and digitoxin from the VICTOR and DIGIT-HF studies.

Oct 17, 2025 · 2 likes · 2 shares · 126 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

Global leaders at @MarkusAtHome Novel developments in the treatment of HFREF - Prof. Dr. John McMurray https://t.co/OzXIyRrIoG via @YouTube

Oct 17, 2025 · 2 likes · 2,414 followers View post →
jorge gamboa
@jorgega62811906 · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 29, 2024 · 13 shares · 65 followers View post →
orion77
@orion7710 · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 29, 2024 · 13 shares · 1,486 followers View post →
Behzad.Fahimi
@BehzadFahimiMD · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 29, 2024 · 13 shares · 70 followers View post →
GN
@GN34976790 · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 14 followers View post →
David Song
@dsongheart · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 293 followers View post →
Lorenzo Fácila
@mi_cardiologo · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 7,938 followers View post →
Nikhil Narang, MD
@Nikhil15 · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 3,044 followers View post →
Chema Fernandez
@chemachir · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 3,834 followers View post →
Niccolo Bonini
@BoniniNiccolo · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 106 followers View post →
soda_troubles,https://med-mastodon.com/@haysam
@set_fortess · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 2,542 followers View post →
juan lopez
@jd1lopez · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 1,075 followers View post →
Viet Le DMSc PA-C FACC FAHA HF-Cert
@VietHeartPA · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 9,787 followers View post →
IMPUNIDAD CERO
@ARAA1981 · X

RT @mvaduganathan: Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n…

Sep 28, 2024 · 13 shares · 489 followers View post →
Muthu Vaduganathan
@mvaduganathan · X

Reductions in clinical events with #ARNI in HF across the LVEF spectrum #PARADIGM chronic HFrEF https://t.co/wkXCn5Yn7n #PIONEER acute HFrEF https://t.co/DMWjmkgP9G #PARALLAX chronic HFmREF/HFpEF https://t.co/Eci3ETX1pD #PARAGON/#PARAGLIDE HFmrEF/HFpEF https://t.co/ud4AMPv0Vf https://t.co/jDufkXk40p

Sep 27, 2024 · 47 likes · 13 shares · 9,128 followers View post →
अरुण
@arun_katwaroo · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Aug 19, 2024 · 16 shares · 213 followers View post →
binsalem
@Abusama2023 · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 20, 2024 · 16 shares · 14 followers View post →
Kananura Keneth
@kkananura · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 17, 2024 · 16 shares · 4,220 followers View post →
Mubarak Modibbo
@Mubaarakm_ · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 17, 2024 · 16 shares · 283 followers View post →
Maina-D
@dmaina37 · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 17, 2024 · 16 shares · 56 followers View post →
AKP
@achyutkris8093 · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 17, 2024 · 16 shares · 5 followers View post →
20151221
@ultraOTD · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 17, 2024 · 16 shares · 2,336 followers View post →
Dr_Tej
@Tejzai6 · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 17, 2024 · 16 shares · 437 followers View post →
jaden
@jaden1493 · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 17, 2024 · 16 shares · 10 followers View post →
auti e sharp
@__peacebeyondme · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 17, 2024 · 16 shares · 1,135 followers View post →
Dr.Muneeb Yusuf
@MuneebDr · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 17, 2024 · 16 shares · 372 followers View post →
Dr.Vaibhav Triapthi MD
@DrVaibhav1992 · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 16, 2024 · 16 shares · 194 followers View post →
Ahmed
@YehiaAhmed99 · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 16, 2024 · 16 shares · 180 followers View post →
Dr Mukesh Palsania
@m_palsania · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 16, 2024 · 16 shares · 1,518 followers View post →
Nritya Trivedi
@NrityaTrivedi · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 16, 2024 · 16 shares · 239 followers View post →
Miracle
@sirlucem · X

RT @DoctorBhavsar: Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X h…

Jun 16, 2024 · 16 shares · 2,393 followers View post →
Yash
@DoctorBhavsar · X

Sacubitrill-valsartan (Entresto), is the backbone of HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X https://t.co/lwWgIQ7BiE

Jun 16, 2024 · 94 likes · 16 shares · 3,849 followers View post →
Yash
@DoctorBhavsar · X

Sacubitrill-valsartan (Entresto), is the backbone if HFrEF now ! Source : PARDIGM-HF trial https://t.co/5MsE791v7X https://t.co/I71TBFowY9

Jun 16, 2024 · 1 like · 3,849 followers View post →
Prof Derek Connolly
@DrDerekConnolly · X

@TribelessSapien the original study versus enalapril was strongly positive https://t.co/kQu0BO1UD5

Mar 3, 2024 · 2 likes · 3,932 followers View post →
Jacob de Wolff
@jfdwolff · X

@Wethepeople1232 @walinjom The only cure would be cardiac transplantation. This is sometimes done in advanced heart failure when it affects people who are otherwise fit enough to undergo a transplant. Drugs such as Entresto improve morbidity and mortality in HFrEF. https://t.co/PHbnVoJJIx

Oct 19, 2023 · 11,275 followers View post →
Gregg Fonarow MD
@gcfmd · X

@kaulcsmc PARADIGM-HF On March 28, 2014, at the third interim analysis, the committee informed the two coprincipal investigators that the prespecified stopping boundary for an overwhelming benefit had been crossed for CV death and for the primary composite https://t.co/IAuqhHs9AE

Oct 10, 2023 · 5 likes · 11,761 followers View post →
Rhys Williams
@RhysWMPharm · X

2/ Angiotensin receptor-neprilysin inhibitor (#ARNI; #sacubitril/valsartan) compared with #enalapril in patients with #HFrEF #PARADIGM-HF https://t.co/33g5v4IxX7

Oct 3, 2023 · 1,196 followers View post →
Josh Wilcox
@jdrwilcox · X

PARADIGM-HF, NEJM 2014. Most of my timeline v familiar I’d imagine: https://t.co/LNcLqVpWRV

Sep 7, 2023 · 1,139 followers View post →
Fizz-DI＠比較と使い分け-KOJIMA Yushi
@Fizz_DI · X

Aug 27, 2023 · 3 likes · 34,303 followers View post →
Jan Hansel
@VirtueOfNothing · X

@load_dependent I believe PARADIGM-HF was also criticised for that way back when … https://t.co/BkLJxlH0rX

Jun 7, 2023 · 2 likes · 4,322 followers View post →
Miguelandry Perez
@DrMiguelandry · X

Disponible en: https://t.co/qv21mRXlxI #ICC #insuficienciacardiaca #heart #heartfailure #corazon #cardiologia #medicinainterna #medicinacritica #neprilisyn #ARNI #neprilisina #ArticuloDeLaSemana #educacionmedicacontinua #drmiguelandry https://t.co/2egp7PPMV1

Jun 5, 2023 · 2 likes · 561 followers View post →
@MARTINSVEL
@MARTINSVEL · X

RT @javier20ch: ✍️Artículos originales:

May 6, 2023 · 12 shares · 412 followers View post →
Faby G.
@Fabiolaghh · X

RT @javier20ch: ✍️Artículos originales:

May 6, 2023 · 12 shares · 412 followers View post →
Fabyyfabiang
@Fabyyfabiang · X

RT @javier20ch: ✍️Artículos originales:

Feb 27, 2023 · 12 shares · 89 followers View post →
Jesal
@Jesal191 · X

RT @javier20ch: ✍️Artículos originales:

Feb 24, 2023 · 12 shares · 27 followers View post →
Jamesoto
@Jamesoto14 · X

RT @javier20ch: ✍️Artículos originales:

Feb 23, 2023 · 12 shares · 216 followers View post →
Diego Esteban Revelo
@DRdiegorevelo · X

RT @javier20ch: ✍️Artículos originales:

Feb 19, 2023 · 12 shares · 42 followers View post →
Edward Scissorhands
@Druidaeduardo · X

RT @javier20ch: ✍️Artículos originales:

Feb 17, 2023 · 12 shares · 1,121 followers View post →
Santiago Oquendo MD
@rksanti · X

RT @javier20ch: ✍️Artículos originales:

Feb 15, 2023 · 12 shares · 4,106 followers View post →
David rojas
@Davidgaleno23 · X

RT @javier20ch: ✍️Artículos originales:

Feb 14, 2023 · 12 shares · 45 followers View post →
lucero
@lucymatsu · X

RT @javier20ch: ✍️Artículos originales:

Feb 14, 2023 · 12 shares · 153 followers View post →
MercheRC
@rc_merche · X

RT @javier20ch: ✍️Artículos originales:

Feb 14, 2023 · 12 shares · 312 followers View post →
Juan Carlos Obaya
@jcobaya69 · X

RT @javier20ch: ✍️Artículos originales:

Feb 14, 2023 · 12 shares · 856 followers View post →
Dr. FEVI
@javier20ch · X

✍️Artículos originales:

Feb 14, 2023 · 18 likes · 12 shares · 13,370 followers View post →
Alejandro Velázquez......
@alexcardio1108 · X

Un ejemplo de estos estudios raros https://t.co/wTmkLwas83 https://t.co/uMOrwBB5VK

Jan 17, 2023 · 332 followers View post →
Abdulraooph
@aboujamal01 · X

RT @drhungo: PARADIGM - HF Angiotensin–Neprilysin Inhibition vs Enalapril in

Jan 6, 2023 · 2 shares · 192 followers View post →
Clinical cardiology
@Mahmoud33986639 · X

RT @drhungo: PARADIGM - HF Angiotensin–Neprilysin Inhibition vs Enalapril in

Jan 6, 2023 · 2 shares · 240 followers View post →
Dr Rob
@drhungo · X

PARADIGM - HF Angiotensin–Neprilysin Inhibition vs Enalapril in

Jan 6, 2023 · 6 likes · 2 shares · 3,189 followers View post →
Abdulaziz Al-Shaibi
@AbdulazizShaibi · X

@SeeFisch ARNI is superior to ACEi/ARB as seen in the PARADIGM-HF trial. Still interchangeable in the guidelines but if a patient can afford ARNI or is not improving on ACEi/ARB he should be switched. https://t.co/vsdakuTrgK

Jan 2, 2023 · 5 likes · 1 share · 416 followers View post →
Maya Guglin
@MGuglin · X

@VPrasadMDMPH @vkprasadlab Example from Cardiology. The PARADIGM-HF https://t.co/BqoLWzWBuc. Entresto= combination of valsartan 160mg BID (max dose) plus unknown (neprilysin inhibitor). The way to randomize was vs valsartan 160 mg BID+placebo. Instead they compared with lisinopril 10 mg BID (half max dose)

Jan 1, 2023 · 589 followers View post →
Rampradeep
@Rampradeep470 · X

PARADIGM-HF : Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure - LCZ696 (at a dose of 200 mg twice daily) vs enalapril (at a dose of 10 mg twice daily), in addi­tion to recommended therapy. #MedTwitter

Dec 22, 2022 · 5 likes · 1,027 followers View post →
手取りすくな
@summerbody321 · X

https://t.co/hrqCE6OXmS https://t.co/sm72bETJHy

Dec 3, 2022 · 82 followers View post →
Rudolf de Boer
@rudolf_deboer · X

@HuisartsAlida Bijwerkingenprofiel is ook onderzocht Alida. Entresto in vergelijking met enalapril zorgt voor minder symptomen en beperkingen (betere kwaliteit van leven), minder nierfunctiestoornissen, minder hyperkaliemie en minder kriebelhoest. https://t.co/5gjufAjMFU

Oct 1, 2022 · 905 followers View post →
JHod
@jhod · X

RT @Doc_Hieu: #NWBO Comparing to what I know, heart failure requires combination treatment (ace/arb, beta blocker, sglt2, etc…) When Entres…

May 31, 2022 · 2 shares · 840 followers View post →
Future
@Doc_Hieu · X

#NWBO Comparing to what I know, heart failure requires combination treatment (ace/arb, beta blocker, sglt2, etc…) When Entresto (blockbuster drug) was published in NEJM it was a big deal. All cause mortality HR 0.84, DCVax-L HR 0.80. This is a BIG DEAL! https://t.co/2yUPfbV8n5

May 25, 2022 · 6 likes · 2 shares · 754 followers View post →
Kamol
@KamolMU · X

RT @accpcardprn: #TBT PARADIGM-HF Trial

Apr 15, 2022 · 6 shares · 101 followers View post →
Kate Morgan DNP, ACNP-BC, HF-Cert, AACC
@KmorganDNP · X

RT @accpcardprn: #TBT PARADIGM-HF Trial

Apr 15, 2022 · 6 shares · 200 followers View post →
A WOMANS DAY
@sondrawomen · X

RT @accpcardprn: #TBT PARADIGM-HF Trial

Apr 14, 2022 · 6 shares · 1,226 followers View post →
ACCP Cardiology PRN
@accpcardprn · X

#TBT PARADIGM-HF Trial

Apr 14, 2022 · 19 likes · 6 shares · 9,286 followers View post →
イシヤク | 医師向け薬剤比較アプリ
@IshiyakuApp · X

エンレスト主要臨床試験 【PARADIGM-HF試験】 NYHAⅡ度以上かつ左室駆出率（LVEF）40%以下（後に35%以下に改訂）の心不全患者に対して、ARNI投与群はACE阻害薬と比較して、心血管死と心不再入院の複合イベントリスクを20％減少させ、死亡率・心不全再入院も有意に減少させた。 https://t.co/osXduH47v7

Mar 10, 2022 · 4 likes · 19,178 followers View post →
Florian Custodis
@floriancustodis · X

RT @gunnar_heine: @ChristophMaack @Dominik_Linz @YouTube @DGK_org @DZHI_Wuerzburg HOMe and away! Alles Gute Euch für 2022, und weitere geme…

Jan 2, 2022 · 1 share · 750 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

@ChristophMaack @Dominik_Linz @YouTube @DGK_org @DZHI_Wuerzburg HOMe and away! Alles Gute Euch für 2022, und weitere gemeinsame Projekte wie https://t.co/X1X0gzv7bY!

Jan 2, 2022 · 2 likes · 1 share · 2,325 followers View post →
にいやん
@niiyan51 · X

Angiotensin-neprilysin inhibition versus enalapril in heart failure https://t.co/fDpdWWQpLE

Dec 15, 2021 · 1,074 followers View post →
Conrad Macon
@cjmacon · X

PARADIGM-HF (DOI: 10.1056/NEJMoa1409077) less ⬇️ eGFR w ARNIs than renal protective medication enalapril (-1.61 vs. -2.04; p < 0.001) Increase in urinary albumin/Cr ratio (1.20 vs. 0.90; p < 0.001) (But they excluded eGFR <30) https://t.co/Or7asEHbyY

Dec 6, 2021 · 7 likes · 387 followers View post →
pinacol
@pinacol · X

【S22-2】ARNIは30<eGFR<60mL/min/1.73m^2の患者でも有効であり、SCrやKの増加はACE阻害薬より少ないかもしれない。 https://t.co/eNKN1C5R0I #jsphcs2021

Nov 13, 2021 · 1 like · 1,611 followers View post →
pinacol
@pinacol · X

【S21-4】ARNIはACE阻害薬やARBと比較して症候性低血圧の頻度が高い。 https://t.co/eNKN1C5R0I https://t.co/3u3MzXOnm1 https://t.co/ZcEhsanorH #jsphcs2021

Nov 13, 2021 · 1 like · 1,611 followers View post →
David León Jiménez
@drleonjimenez · X

@quequesierra ARNI LCZ696 produjo una reducción de la mortalidad total del 16% frente a enalapril (17,0% vs. 19,8%, HR 0,84, IC 95% 0,76-0,93, p<0,001); en el 13,3% vs. 16,5%, respectivamente, la muerte fue de causa cardiovascular (HR 0,80, IC 95% 0,71-0,89, p<0,001). https://t.co/8MFhZfEWIb

Oct 22, 2021 · 1,120 followers View post →
Dr. bycomet
@bycomet · X

エンレスト（一般名：サクビトリルバルサルタンナトリウム水和物） / “Angiotensin-neprilysin inhibition versus enalapril in heart failure - PubMed” https://t.co/p3cd2yki7s

Oct 17, 2021 · 1 like · 7,953 followers View post →
Fatima Villafañe Sanz
@FatimaVillaf · X

#JornadacardiovascularSEMG, #NuevasGuíasEuropeasEnIC @escardio @SEMG_ES @semg_madrid @SEMG_ES señalan la preferencia de ARNI sobre IECA. ¿Cuál es la razón? El estudio PARADIGM-HF compara ARNI con IECA https://t.co/jp28Ci4hbj

Oct 2, 2021 · 1 like · 466 followers View post →
鯵ゼミ_Journal Club
@AJSR_since2005 · X

#011 Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure N Engl J Med 2014;371:993-1004.

Sep 4, 2021 · 6 followers View post →
Gunnar Henrik Heine
@gunnar_heine · X

ESC Leitlinien Herzinsuffizienz - Prof. Maack (Würzburg) https://t.co/X1X0gzv7bY via @YouTube

Aug 28, 2021 · 1 like · 2,325 followers View post →
Nader Joghetaei, MD
@naderjo · X

RT @KardiologieHH: @MarcVorpahl @AGIKinterv @DGK_org @YoungDgk @naderjo @ViclouiseJ @kaschenke @kardiologie_org @mirvatalasnag #radialfirst…

Jul 7, 2021 · 2 shares · 1,577 followers View post →
Marc M. Vorpahl, MD
@MarcVorpahl · X

RT @KardiologieHH: @MarcVorpahl @AGIKinterv @DGK_org @YoungDgk @naderjo @ViclouiseJ @kaschenke @kardiologie_org @mirvatalasnag #radialfirst…

Jul 7, 2021 · 2 shares · 2,441 followers View post →
Erik Rafflenbeul
@KardiologieHH · X

@MarcVorpahl @AGIKinterv @DGK_org @YoungDgk @naderjo @ViclouiseJ @kaschenke @kardiologie_org @mirvatalasnag #radialfirst: Matrix (https://t.co/5aHzDnWZAj by @vlgmrc) #HeartFailure: PARADIGM-HF (https://t.co/5hKuaqIky0)

Jul 7, 2021 · 5 likes · 2 shares · 8,692 followers View post →
Lorenzo Gutiérrez
@Lojoga · X

@quequesierra Aquí el resultado en el @NEJM https://t.co/psDZZ1qtgS y el protocolo https://t.co/TsIFBgkcF0

Jun 29, 2021 · 2 likes · 579 followers View post →
Ainaproxeno
@AiiinaaBartoll · X

@quequesierra https://t.co/U4PyzYbXyd este puede ser?

Jun 29, 2021 · 851 followers View post →
Nelson Alvarez
@nelson_alv · X

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. PARADIGM-HF, acrónimo de Prospective Comparison of ARNI with ACEI to Determine Impacto on Global Mortalilty and Morbility in Heart Failure https://t.co/5yySt8mZHN

Jun 7, 2021 · 1,035 followers View post →
john morley
@drjohnmorley · X

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM https://t.co/0wgqM3AoyQ

May 14, 2021 · 8,325 followers View post →
Shibley
@dr_shibley · X

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM https://t.co/6ZLJaZcNOD

May 14, 2021 · 1 like · 27,512 followers View post →
ときヲ
@toki_wo_koe · X

ARNIで肝障害だと？ なんでも起こりそうではあるが、PARADIM-HFのSupplementary Appendixをみても全く報告がない。程度の問題でしょうか？ 経験ある方、どれぐらいいるのでしょうか。 #ARNI https://t.co/YHOCFxcASS

Apr 26, 2021 · 1 like · 1 share · 2,583 followers View post →
Yasser UMKCRCT
@ymhs92 · X

PARADIGM-HF: The use of ARNI (LCZ696) in patients with HFrEF was associated with significant reductions in death (both all-cause and cardiovascular), and hospitalizations for HF compared with enalapril #UMKCRCT https://t.co/Crxs227dDK

Apr 11, 2021 · 10 followers View post →
加藤隆寛
@tak_pharmacist · X

エンレストはエナラプリル20mg/dayに対して有意なアウトカム改善を示したので、10mg/dayまでしか使えない日本ではさらにベネフィットが得られる可能性がある反面、エナラプリル20mgより血圧下げてるのでどれだけの症例で200mgまで増量できるかは気になるところです。#心不全 https://t.co/8TzpZXTT7x

Mar 7, 2021 · 400 followers View post →
Paula Smith
@MissPaulaSmith1 · X

RT @AAlMohammad87: Mortality of patients with #HFrEF improved with better therapeutics. Based on the placebo arms of #PARADIGM and #DAPA_HF…

Feb 5, 2021 · 2 shares · 127 followers View post →
Mark Green
@Markgreen433 · X

RT @AAlMohammad87: Mortality of patients with #HFrEF improved with better therapeutics. Based on the placebo arms of #PARADIGM and #DAPA_HF…

Feb 4, 2021 · 2 shares · 902 followers View post →
Abdallah Al-Mohammad
@AAlMohammad87 · X

Mortality of patients with #HFrEF improved with better therapeutics. Based on the placebo arms of #PARADIGM and #DAPA_HF, the mortality was 19.8% at 27 months and 13.9% at 18 months, respectively @BSHeartFailure @NEJM DOI: 10.1056/NEJMoa1409077 DOI: 10.1056/NEJMoa1911303

Feb 4, 2021 · 3 likes · 2 shares · 923 followers View post →
Gustavo Lenci Marques MD, PhD
@LenciMarques · X

2014: Impossível não colocar nesse ano o PARADIGM HF. Esse estudo demonstrou uma redução expressiva da mortalidade cardiovascular em pacientes com IC com Fração de Ejeção Reduzida com o uso de sacubitril-valsartana em relação aos IECA ref: https://t.co/cOZuu64HSK

Dec 26, 2020 · 415 followers View post →
ねこりん
@ne_co_rin_ · X

Angiotensin-neprilysin inhibition versus enalapril in heart failure https://t.co/GJCZXgpQYu

Dec 13, 2020 · 242 followers View post →
Abdallah Al-Mohammad
@AAlMohammad87 · X

#PARADIGM N Engl J Med 2014; 371:993-1004 DOI: 10.1056/NEJMoa1409077

Nov 22, 2020 · 923 followers View post →
DrBecher
@DrBeat019 · X

https://t.co/Anz28cE1KH https://t.co/SArUQx4nX6 https://t.co/BGIePb7KIv https://t.co/5diz3kBEv2

Oct 24, 2020 · 913 followers View post →
Juan Senior
@jsenior64 · X

https://t.co/5XfLi2DQHE

Sep 4, 2020 · 1 like · 11,064 followers View post →
Jessica Wang, MD, MPH
@MultitaskingMD · X

RT @NUIM_Chiefs: #Pearl 3: For HFrEF patients (NYHA II/III) who tolerate an ACE inhibitor or ARB, replace with ARNI after washout period.…

Aug 4, 2020 · 1 share · 190 followers View post →
Northwestern IM Chiefs
@NUIM_Chiefs · X

#Pearl 3: For HFrEF patients (NYHA II/III) who tolerate an ACE inhibitor or ARB, replace with ARNI after washout period. https://t.co/44GCcLiNwt

Aug 4, 2020 · 3 likes · 1 share · 1,472 followers View post →
青島周一
@syuichiao89 · X

サクビトリル・バルサルタン HFrEF https://t.co/RoWmfxqcSN HFpEF https://t.co/nNSVZZLp1N Acute Heart Failure https://t.co/AuxhpB0Glb

Jul 23, 2020 · 1 like · 8,602 followers View post →
カス
@kspharmacist · X

ARNI ACEiは併用を避けなければいけないようだし（ブラジキニン過剰回避），もともとARB服用している場合は重複に気をつけないといけない割りに，大した効果もなさそうだし(https://t.co/m4GUKL5BBB)，なかなか使いづらそうな第一印象^^; https://t.co/hTiHSPiyBF

May 28, 2020 · 3 likes · 1 share · 642 followers View post →
Coastal Longevity
@CoastalLong757 · X

Landmark PARADIGM - HF Trial for Heart Failure with reduced Ejection Fraction (HFrEF) https://t.co/62n0Gw09u4 #Cardiovascularhealth #Cardiology #Cardiovasculardisease #Hearthealth… https://t.co/JusTJ9giky

May 12, 2020 · 108 followers View post →
heiderespinel
@heiderespinel · X

RT @jsenior64: https://t.co/Lp3V0zpG9f

Apr 26, 2020 · 1 share · 423 followers View post →
Juan Senior
@jsenior64 · X

https://t.co/Lp3V0zpG9f

Apr 26, 2020 · 1 share · 11,064 followers View post →
VCU IM Residency
@VCU_IMRes · X

RT @DrJaredDyer: #MRPearls PARADIGM-HF showed a modest rise in BNP levels (~20%) after starting Entresto with the peak occurring ~8 weeks a…

Apr 21, 2020 · 1 share · 1,693 followers View post →
Jared Dyer, DO
@DrJaredDyer · X

#MRPearls PARADIGM-HF showed a modest rise in BNP levels (~20%) after starting Entresto with the peak occurring ~8 weeks after starting therapy. https://t.co/ijWUzWMd0z @VCU_IMRes @AudreyBJernigan @JCHillyard @AjayPMD @jaideeppatelmd

Apr 21, 2020 · 2 likes · 1 share · 912 followers View post →
RONALD LUKE
@RONALD41077142 · X

Two molecules vs one, never fair! https://t.co/JTjIp5n0Mt

Feb 27, 2020 · 1 like · 16 followers View post →
Brahmajee Nallamothu
@bnallamo · X

We'll accompany this with the contemporary PARADIGM-HF trial that demonstrated a mortality benefit of angiotensin-neprilysin inhibition over enalapril. https://t.co/45OqSdDz0W

Feb 25, 2020 · 9 likes · 3,435 followers View post →
RR BaligaMD, Professor & Cardiologist
@RRBaligaMD · X

@DrMarthaGulati @HeartBobH @American_Heart @AHAMeetings @RonBlankstein @fischman_david @SVRaoMD @DocSavageTJU @cardioPCImom @mmamas1973 @iamritu @hvanspall Yes but slow-adopter after PARADIGM-HF | Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM https://t.co/SxTmJm4QnD

Nov 17, 2019 · 1,404 followers View post →
RR BaligaMD, Professor & Cardiologist
@RRBaligaMD · X

Yes but slow adopter after PARADIGM-HF Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure | NEJM https://t.co/SxTmJm4QnD https://t.co/lWsy8Gu2cp

Nov 17, 2019 · 1 like · 1,404 followers View post →
British Geriatrics Society
@GeriSoc · X

Recommended reading: Angiotensin-Neprilysin inhibition versus Enalapril in Heart Failure https://t.co/Zrl1jVaCfn #BGSconf

Nov 8, 2019 · 3 likes · 37,362 followers View post →
Juan Senior
@jsenior64 · X

El PARADIGM HF empezó toda la historia. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure https://t.co/Lp3V0zpG9f

May 28, 2019 · 5 likes · 11,064 followers View post →
FOAM Cards
@FOAM_Cards · X

(1/2)Trial of the day: PARADIGM-HF McMurray JJV, et al. "Angiotensin-neprilysin inhibition versus enalapril in heart failure". The New England Journal of Medicine. 2014. 371(11):993-1004. https://t.co/BhtIsIJz2c #FOAMcards

Jan 25, 2019 · 68 followers View post →